3 Undervalued Stocks To Buy Now For September 2026

Person checks banal marketplace capacity connected phone, while there's a surface of a banal successful the background. The champion undervalued stocks for September see 3 stocks investors whitethorn see up of upcoming net reports.

getty

After watching what moves stocks for decades, I’ve travel to a elemental conclusion: banal prices move up erstwhile companies study amended than expected results and raise their forecasts. Applying this norm leads to 3 stocks investors whitethorn see erstwhile looking for banal to bargain up of their adjacent net reports.

Top Undervalued Stocks To Buy Now In September 2026

More specifically, I looked for 3 publicly-traded companies that person beaten statement financial targets and raised guidance successful much than 1 consecutive 2026 quarter, waste and acquisition beneath assemblage aliases humanities multiples to income aliases earnings, and study their results this coming September aliases October.

Three companies, Micron Technology, Jabil and The Cigna Group, fulfill these criteria. Micron has the strongest competitory position of the 3 companies. More specifically, the institution benefits from being a starring supplier of representation chips – a scarce assets successful precocious request owed to precocious AI superior expenditures. However, since Micron’s shares person soared successful 2026, the institution must hit and raise supra expectations for the banal to proceed rising.

Jabil, which provides statement manufacturing services, is little exposed to the soaring request resulting from AI superior expenditures. However, the institution is expected to raise guidance aft reporting its results successful September. Meanwhile, Cigna could emergence if investors backmost distant from the AI waste and acquisition and displacement superior to alleged protect stocks apt not to suffer from the bursting of the AI bubble.

1. Micron Technology (MU)

MU Business Overview

• Current stock value (Aug. 18): $1,012
• Sector / industry: Semiconductors; representation (DRAM, NAND, HBM)
• Revenue maturation (latest quarter): Revenue $41.46 billion, up 346%
• Net Margin (latest quarter): 55.9%
• Free rate travel (latest quarter): $18.3 billion
• Valuation (Aug. 18): Trailing P/E 22.83, guardant P/E 7.04

Micron is the only awesome U.S.-based representation chipmaker and 1 of the "Big Three" DRAM/NAND producers alongside Samsung and SK Hynix. Micron’s products – peculiarly precocious bandwidth representation which are optimized to activity pinch Nvidia AI chips – are successful specified request that the institution cannot proviso each its customers – creating an opportunity to raise prices.

Why MU Stock Is A Top Choice

Micron is simply a apical prime because of beardown contracted demand; a shape of beating targets and raising guidance; and a comparatively debased valuation.

• There is simply a representation shortage and the company’s capacity is sold-out backed by contracted revenue. Management states HBM3E and HBM4 are afloat booked done almanac 2027 pinch request extending into 2028. Per Micron's Fiscal Q3 2026 earnings-call prepared remarks, the institution has signed 16 strategical customer agreements (SCAs) carrying astir $100 cardinal successful minimum contracted revenue. Micron is capable to meet the request of its cardinal customers “only astir 50% to astir 2 thirds." of the time, CEO Sanjay Mehrotra told Bloomberg.
• A demonstrated shape of beating its ain guidance and raising the bar. Fiscal Q3 revenue of $41.46 cardinal hit management's $33.5 cardinal guideline by astir 24%, and the institution past guided fiscal Q4 to a grounds $50 cardinal pinch astir 86% gross separator and astir $31 EPS. Repeated ample upside surprises make different hit plausible.
• A valuation that remains debased contempt the run. A guardant P/E adjacent 6 and a PEG astir 0.04 are extraordinarily debased versus a semiconductor manufacture median guardant P/E supra 30, leaving room for aggregate description if the super-cycle persists.

MU Key Risks

Its cardinal risks are the semipermanent cyclicality of the representation business, the stock’s ample summation truthful acold successful 2026 and rising superior costs that could unit free rate flow.

• Micron is successful the cyclical representation spot business and pricing tin reverse sharply. Coordinated capacity additions from Micron, SK Hynix and Samsung could yet normalize prices. The extraordinarily debased guardant P/E partially reflects the marketplace pricing successful an eventual net peak.
• The banal has already risen importantly this year, trading beneath its intraday precocious of $1,255.00, truthful volatility is precocious – pinch a beta of 2.2.
• Micron expects its superior expenditures to emergence 67% truthful the institution tin build the capacity to meet precocious demand. If request softens successful this highly cyclical industry, capex could unit free rate flow, according to Quartr.

2. Jabil (JBL)

JBL Business Overview

• Current stock value (Aug. 18): $370
• Sector / industry: Electronic manufacturing services; exertion hardware
• Revenue maturation (most caller quarter): Revenue $8.75 billion, up 11.8%
• Net separator (most caller quarter): 2.6%
• Free rate travel (most caller 12 months): $1.4 billion
• Valuation (Aug. 18): Trailing P/E 46.23, guardant P/E 23.41

Jabil provides engineering, supply-chain and manufacturing services. Its fastest-growing unit, Intelligent Infrastructure, builds AI data-center hardware. Jabil besides serves automotive, healthcare and digital-commerce markets.

Why JBL Stock Is A Top Choice

Jabil is simply a apical prime because it has a shape of beating and raising and location is simply a catalyst to thrust up the banal successful September; gross is speeding up owed to AI superior expenditures and valuation is reasonable fixed the growth.

• Jabil hit and raised full-year guidance successful some fiscal Q2 and fiscal Q3 2026. It lifted its fiscal twelvemonth 2026 gross outlook to $35 billion, halfway EPS to $12.70, and free rate flow to greater than $1.4 billion. The company’s fiscal 4th fourth study — expected successful precocious September — will hap astatine the aforesaid clip arsenic the company’s Annual Investor Briefing, wherever guidance is expected to rumor general fiscal twelvemonth 2027 guidance. CEO Mike Dastoor has already signaled successful the latest net conference telephone AI-related maturation successful FY2027 of astir 50% connected a larger base.
• Accelerating AI revenue. In the company’s June net call, guidance raised expectations connected AI-related gross by $500 cardinal from the company’s March outlook.
• Reasonable valuation for the maturation profile. At a guardant P/E of 22.98 — beneath the hardware manufacture median of astir 30 — pinch mid-teens gross maturation and rising margins, Jabil is inexpensive comparative to AI-infrastructure peers, and analysts person many times raised value targets (JPMorgan to $450 and Argus to $475), noted CNN.

JBL Key Risks

Key risks of JBL see the company’s precocious dependence connected AI, its higher banal value that has constricted imaginable upside and the bladed margins successful the manufacturing services industry.

• Portfolio concentration: Intelligent Infrastructure whitethorn transcend 50% of revenue, expanding vulnerability to a imaginable AI-capex slowdown.
• Much higher banal price: With the banal value having risen, immoderate analysts see the banal afloat valued.
• Thin margins successful manufacturing services: A humble free-cash-flow separator limits the cushion if request aliases pricing weakens.

3. The Cigna Group (CI)

CI Business Overview

• Current stock value (Aug. 18): $275
• Sector / industry: Health care; wellness security and services
• Revenue maturation (most caller quarter): Revenue $71.7 billion, up 7%
• Net separator (most caller quarter): 2.3%
• Free rate travel (latest 12 months): $9.11 cardinal up 131%
• Valuation (Aug. 18): Trailing P/E 11.39, guardant P/E 8.7

The Cigna Group provides wellness services done 2 business segments. Its Evernorth Health Services portion competes successful the drugstore use management, specialty drugstore and attraction services segments. Cigna Healthcare provides aesculapian security to U.S. and world customers.

Why CI Stock Is A Top Choice

Cigna banal is simply a apical prime because the institution consistently thumps and rises; its valuation is profoundly discounted compared to peers, and rate procreation is growing.

• Consistent thumps and steadily rising guidance. Cigna hit Q2 2026 adjusted EPS —$7.78 versus $7.59 statement —and raised full-year adjusted EPS guidance to astatine slightest $30.45, continuing a shape of upward revisions; guidance reiterated a 10% to 14% semipermanent EPS maturation forecast, according to a company release.
• Deep valuation discount to peers and its ain history. A guardant P/E nether 10 is astir 27% beneath Cigna's ain 10-year mean and good beneath the managed-care and broader healthcare sector. This spread could adjacent quickly if medical-cost fears easiness and the 2027 drugstore use guidance trading play proves lucrative, notes Full Ratio.
• Strong, increasing rate procreation and buybacks. The $7.7 cardinal free rate travel (up 27%) and astir $9 cardinal full-year operating FCF guidance money stock repurchases, which support EPS maturation and downside valuation, noted SeekingAlpha.

CI Key Risks

The cardinal risks for Cigna banal are antagonistic caller expert ratings and rising aesculapian costs.

• Negative near-term expert momentum: Raymond James downgraded CI to Outperform from Strong Buy connected Aug. 3, and Jefferies trim it to Hold from Buy connected Aug. 4 (target to $307 from $336), citing that the EviCore waste could trim Cigna’s adjusted operating income to astir 10% beneath the expert statement estimate.
• Medical-cost inclination risk: PwC’s Behind the Numbers 2026 report projects a group aesculapian costs inclination of astir 8.5% to 9.0% for 2026 and Cigna guidance flagged that immoderate Q2 benefits (specialty generics/biosimilars) will not repetition astatine the aforesaid level.

Micron Technology – a momentum banal – and Jabil – fitting the maturation astatine a reasonable value model; are apt to use from beardown AI superior expenditures. However, for protect investors seeking to protect against a downturn successful the AI trade, Cigna could beryllium a bully fit. Analyzing the stock marketplace outlook for the past months of 2026 whitethorn besides beryllium important for investors to consider.